Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss?

If you’re weighing semaglutide against tirzepatide, you’re asking the right question. These two drugs have completely changed obesity treatment — and they’re the most effective peptides for weight loss available today — but they work differently, produce different results, and come with different trade-offs.

We now have a direct head-to-head trial (SURMOUNT-5), published in the New England Journal of Medicine in 2025, that finally settles the efficacy debate with hard numbers [1]. Here’s what the science actually says.

Key Takeaways

Tirzepatide produces roughly 50% more weight loss than semaglutide — 20.2% vs 13.7% body weight reduction at 72 weeks in head-to-head testing [1]
Tirzepatide targets two receptors (GIP + GLP-1) while semaglutide targets only GLP-1 — this dual mechanism appears to drive the difference
Gastrointestinal side effects are similar between both drugs, though nausea rates differ slightly at certain doses [2]
Both drugs require ongoing use — weight regain after stopping is well-documented for each

How They Work: GLP-1 vs Dual GIP/GLP-1
The Clinical Trial Data
Head-to-Head: SURMOUNT-5
Side Effect Comparison
Dosing and Titration
Cost Comparison
Which Is Better for You?
Side Effects and Safety
FAQ
Sources

How They Work: GLP-1 vs Dual GIP/GLP-1

Semaglutide (brand names Ozempic and Wegovy) is a GLP-1 receptor agonist — one of several types of peptide therapy now available. It mimics a gut hormone called glucagon-like peptide-1 that your body naturally releases after eating. GLP-1 slows gastric emptying, reduces appetite through brain signaling, and improves insulin sensitivity [3].

Tirzepatide (brand names Mounjaro and Zepbound) does all of that — plus it also activates the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that plays a role in fat metabolism and energy balance [4].

Think of it this way: semaglutide pushes one button that suppresses appetite. Tirzepatide pushes two buttons simultaneously.

Why GIP Matters

For years, researchers weren’t sure GIP agonism would help with weight loss. Some early theories even suggested blocking GIP might be better. The SURMOUNT trials proved otherwise. The dual mechanism appears to enhance caloric deficit through complementary pathways — better insulin signaling from GIP combined with stronger appetite suppression from GLP-1 [4].

The GIP receptor is also expressed in the brain and adipose tissue. Emerging research suggests GIP signaling in the hypothalamus may independently reduce food intake through mechanisms separate from GLP-1 [5].

The Clinical Trial Data

Semaglutide: The STEP Trials

The STEP program established semaglutide 2.4 mg (Wegovy) as a powerful obesity treatment.

STEP 1 (2021, NEJM): 1,961 adults with obesity or overweight. At 68 weeks, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight compared to 2.4% with placebo. A striking 86.4% of participants achieved at least 5% weight loss [3].

STEP 2 focused on patients with type 2 diabetes, showing 9.6% weight loss at the 2.4 mg dose — lower than STEP 1 because diabetes itself makes weight loss harder [6].

STEP 3 added intensive behavioral therapy and saw 16.0% weight loss, suggesting semaglutide plus serious lifestyle changes can push results further [6].

STEP 5 extended treatment to 104 weeks, confirming weight loss was maintained at 15.2% as long as participants stayed on the drug [6].

Tirzepatide: The SURMOUNT Trials

The SURMOUNT program tested tirzepatide at three doses: 5 mg, 10 mg, and 15 mg.

SURMOUNT-1 (2022, NEJM): 2,539 adults with obesity. At 72 weeks, average weight loss was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo. Among those on the highest dose, 36.2% lost at least 25% of their body weight [7].

Those numbers were unprecedented. No prior obesity drug had produced 20%+ average weight loss in a clinical trial.

SURMOUNT-2 enrolled patients with obesity and type 2 diabetes, showing 12.8% (10 mg) and 14.7% (15 mg) weight loss — again outpacing what semaglutide achieved in a comparable diabetic population [8].

SURMOUNT-3 and SURMOUNT-4 examined tirzepatide after an initial lifestyle intervention and weight maintenance after drug discontinuation, respectively [8].

Head-to-Head: SURMOUNT-5

Until 2025, the semaglutide vs tirzepatide comparison relied on cross-trial comparisons — inherently imperfect because study populations and designs differ. SURMOUNT-5 changed that.

This Phase IIIb trial directly compared tirzepatide (maximum dose 15 mg) against semaglutide (maximum dose 2.4 mg) in 751 adults with obesity or overweight with at least one weight-related comorbidity [1].

The Results at 72 Weeks

Metric	Tirzepatide	Semaglutide
Mean weight loss	20.2%	13.7%
Absolute weight lost	~50 lbs	~33 lbs
≥5% weight loss	94.4%	85.0%
≥10% weight loss	82.8%	68.6%
≥20% weight loss	56.5%	25.6%
≥25% weight loss	35.6%	10.1%

The difference — 6.5 percentage points more weight loss with tirzepatide — was statistically significant (P<0.001) [1].

Put plainly: more than half of tirzepatide users lost over 20% of their body weight. Only about a quarter of semaglutide users hit that mark. For a deeper look at how these drugs specifically target fat mass versus lean mass, see our guide on peptides for fat loss.

Real-World Data Backs This Up

A large JAMA Internal Medicine cohort study (2024) with over 41,000 matched patients found consistent results outside of clinical trials. Tirzepatide users had greater weight loss at all time points measured, confirming the trial findings translate to clinical practice [2].

A 2025 systematic review and meta-analysis pooling data from over 140,000 participants across RCTs and real-world studies found tirzepatide produced an additional 4.23 kg (about 9.3 lbs) of weight loss compared to semaglutide on average [9].

Side Effect Comparison

Both drugs carry gastrointestinal side effects as their most common complaints. This comes with the territory — slowing gastric emptying and altering gut hormone signaling affects digestion.

GI Side Effects in SURMOUNT-5

Side Effect	Tirzepatide	Semaglutide
Nausea	28.4%	31.8%
Diarrhea	21.7%	17.4%
Vomiting	13.2%	13.5%
Constipation	14.1%	11.0%
Discontinuation due to AE	4.3%	1.6%

The GI side effect profiles were broadly similar, though tirzepatide had slightly higher diarrhea and constipation rates while semaglutide had marginally higher nausea [1].

One notable finding: more tirzepatide users discontinued due to adverse events (4.3% vs 1.6%). This may relate to the more aggressive weight loss itself rather than a fundamentally worse side effect profile [1].

Serious Side Effects

Both drugs carry FDA boxed warnings for thyroid C-cell tumors based on animal studies. Neither drug has been linked to increased thyroid cancer in humans so far, but people with a personal or family history of medullary thyroid carcinoma should avoid both [3][7].

Pancreatitis is a rare but reported risk with both. Gallbladder events (gallstones, cholecystitis) occur more frequently — this is expected with rapid weight loss regardless of the method used [10].

A 2025 systematic review of Phase 3 trials reported fewer overall gastrointestinal side effects with tirzepatide 10 mg and 15 mg compared to semaglutide 2.4 mg, despite the greater weight loss [10].

Dosing and Titration

Semaglutide (Wegovy) Dosing

Both are administered as once-weekly subcutaneous injections. Semaglutide follows a 16-week titration:

Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Weeks 9–12: 1.0 mg
Weeks 13–16: 1.7 mg
Week 17+: 2.4 mg (maintenance)

Tirzepatide (Zepbound) Dosing

Tirzepatide uses a 20-week titration to reach the maximum dose:

Weeks 1–4: 2.5 mg
Weeks 5–8: 5.0 mg
Weeks 9–12: 7.5 mg
Weeks 13–16: 10.0 mg
Weeks 17–20: 12.5 mg
Week 21+: 15.0 mg (maximum)

Note that many patients get good results at 10 mg without titrating to 15 mg. Your prescriber may keep you at a lower dose if you’re responding well and tolerating side effects.

Cost Comparison

Both medications are expensive without insurance. List prices as of early 2026:

Drug	Brand (Obesity)	List Price/Month
Semaglutide	Wegovy	~$1,350
Tirzepatide	Zepbound	~$1,060

Zepbound launched at a lower list price than Wegovy and Eli Lilly has offered direct-to-consumer pricing programs. Insurance coverage varies widely — many commercial plans now cover one or both, but prior authorization is almost always required.

With the entry of compounded versions (when available), some patients access semaglutide or tirzepatide at significantly lower cost, though the regulatory landscape here continues to shift.

For patients with type 2 diabetes, the diabetes-labeled versions (Ozempic for semaglutide, Mounjaro for tirzepatide) are typically better covered by insurance.

Which Is Better for You?

There’s no universal answer. Here’s how to think about it:

Tirzepatide may be better if:

You need maximum weight loss (BMI 40+, weight-related health conditions)
You’ve tried semaglutide and plateaued
You also have type 2 diabetes (tirzepatide shows stronger HbA1c reduction) [11]
Cost is manageable or insurance covers it

Semaglutide may be better if:

You’re looking for moderate weight loss (10–15%)
You have more cardiovascular risk — semaglutide has stronger CV outcome data from the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events [12]
You prefer a well-studied medication with a longer track record
Insurance or compounding makes it more accessible

The Cardiovascular Factor

This is worth emphasizing. The SELECT trial (2023, NEJM) demonstrated that semaglutide 2.4 mg reduced major cardiovascular events by 20% in overweight/obese adults with established cardiovascular disease — regardless of whether they had diabetes [12].

Tirzepatide doesn’t yet have equivalent cardiovascular outcome data. The SURPASS-CVOT trial is underway but results aren’t expected until 2027. If you have known heart disease, this is a meaningful difference in the evidence base right now.

Side Effects and Safety

Common Side Effects (Both Drugs)

Nausea — most common, usually worst during titration and improves over time
Diarrhea — more frequent with tirzepatide
Constipation — occurs with both, can be managed with fiber and hydration
Vomiting — usually mild and transient
Injection site reactions — minor redness or irritation
Fatigue and headache — reported in early weeks

Less Common but Serious Risks

Pancreatitis — rare, discontinue immediately if symptoms arise
Gallbladder disease — related to rapid weight loss itself
Thyroid tumors — boxed warning based on rodent studies; not confirmed in humans
Hypoglycemia — rare when used without insulin or sulfonylureas
Gastroparesis-like symptoms — delayed gastric emptying can rarely become problematic

Who Should Not Take These Drugs

Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
History of pancreatitis (relative contraindication)
Pregnant or planning pregnancy
Known hypersensitivity to the drug or excipients

Frequently Asked Questions

Is tirzepatide really better than semaglutide for weight loss?▼

By the numbers, yes. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [1]. That said, “better” depends on your full clinical picture — cardiovascular history, side effect tolerance, insurance coverage, and your weight loss goals all matter.

Can I switch from semaglutide to tirzepatide?▼

Yes, and many patients do — especially those who plateau on semaglutide. Your prescriber will typically start tirzepatide at 2.5 mg and titrate up. There’s no need for a washout period, though expect some GI side effects during the transition as your body adjusts to the new medication.

Do I regain weight when I stop either drug?▼

Unfortunately, yes. The STEP 1 extension study showed participants regained about two-thirds of their lost weight within one year of stopping semaglutide [6]. SURMOUNT-4 showed similar weight regain after tirzepatide discontinuation. Both drugs are currently considered long-term treatments, much like blood pressure medications. For more on what to expect from these and other options, see our full peptides for weight loss guide.

What about the oral versions?▼

Oral semaglutide (Rybelsus) is available for type 2 diabetes, and a higher-dose oral version showed promising weight loss results in the OASIS trial program. Lilly is also developing an oral tirzepatide (orforglipron). These oral options will expand access for people who dislike injections, though they’re not yet widely available for obesity specifically.

Are compounded versions safe?▼

Compounded semaglutide and tirzepatide have been available during drug shortages. The FDA has expressed concerns about quality control at some compounding pharmacies. If you go this route, use a 503B outsourcing facility that’s FDA-registered and follows cGMP standards. The active ingredient is the same, but purity, sterility, and dosing accuracy vary by compounder.

Sources

Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394
Rodriguez PJ, Goodwin Cartwright BM, Grzes S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. PMID: 38976257
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647
Campbell JE, Drucker DJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metab. 2013;17(6):819-837. PMID: 23684623
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 5). JAMA. 2021;325(14):1414-1425. PMID: 33755728
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PMID: 35658024
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275
Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight: A Systematic Review and Meta-Analysis. PMC. 2025. PMC12151102
Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity: A systematic review of Phase 3 clinical trials. ScienceDirect. 2025. doi:10.1016/j.orcp.2025.01.003
Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. PMC. 2025. PMC12579026
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131